Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 760 participants.
Also called NCT04667143
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 760 participants
- Registry
-
NCT04667143
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04667143. Randomized; quadruple masking; primary purpose treatment. Start 2021-01 (anticipated); primary completion 2022-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
- Condition
- Diabetes Mellitus, Type II
- Intervention (Drug)
- Retagliptin, Henagliflozein, metformin XR
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct04667143- Content hash
f2ed0ff42f8a1d9ad368a4da10eee5214ff71b4f14faeff6ef222887c95b490e